Merck/Pfizer anti-PD-L1 therapy first-line maintenance treatment bladder cancer in the United States, Japan and Europe into the review!
Last Update: 2020-08-01
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Source: European Medicines Agency for BAVENCIO ® (avelumab) for First-Line Maintenance Treatment of The Locally Advanced or Metastatic Urothelial Carcinoma Original title: Bladder Cancer Immunotherapy! Merck/Pfizer anti-PD-L1 therapy Bavencio first-line maintenance therapy indications in the United States, Japan and Europe into the review!
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.